Earnings: Page 6
-
Courtesy of Dexcom
Dexcom hails CGM share gains as driver of 25% revenue growth in Q2
International market share gains and expanding coverage in the U.S. led the CGM maker to raise its revenue forecast for 2023.
By Nick Paul Taylor • July 28, 2023 -
Permission granted by Boston Scientific
Boston Scientific raises full-year forecast again, fueled by strong Q2
The company boosted its outlook for the second consecutive quarter and said patients face waitlists for procedures using its devices.
By Susan Kelly • July 27, 2023 -
Courtesy of https://www.edwards.com/devices/heart-valves/transcatheter-SAPIEN-3-Ultra
Edwards’ TAVR results hurt by pandemic aftereffects and competition in Q2
Staffing is still not where Edwards “would have projected to be in absence of the pandemic.”
By Nick Paul Taylor • July 27, 2023 -
Tim Boyle via Getty Images
Baxter progresses with planned kidney care spinoff, expects biopharma solutions sale this quarter
The company expects hospital spending to increase in the second half of the year amid rising procedure volumes and a stabilizing supply chain.
By Elise Reuter • July 27, 2023 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Demand for 4-in-1 test helps Danaher’s COVID sales beat internal forecast
Danaher said it is continuing to take market share as many customers look to consolidate their point-of-care PCR testing platforms.
By Nick Paul Taylor • July 26, 2023 -
Courtesy of GE Healthcare
GE HealthCare plans cost cuts, raises earnings forecast
The company plans to improve its margins by cutting down on service agreements and by driving more efficiency in manufacturing and supply chain.
By Elise Reuter • July 25, 2023 -
Courtesy of Philips
Philips reports 9% sales jump, in rebound from sleep device recall
Litigation and a U.S. Justice Department investigation into the recall are ongoing, as are discussions on a proposed consent decree.
By Susan Kelly • July 24, 2023 -
Courtesy of Intuitive Surgical
Bariatric surgery slowdown nips Intuitive Surgical’s Q2 procedure growth
New weight-loss drugs are eroding demand for surgical procedures that employ the company’s robotic systems.
By Susan Kelly • July 21, 2023 -
Courtesy of Abbott
Abbott Q2 net profit falls as weaker COVID test sales drag on revenue
Stronger medical device sales and a recovery in the infant formula business partly offset the impact of reduced COVID-19 testing.
By Susan Kelly • July 20, 2023 -
Mario Tama via Getty Images
J&J earnings a ‘positive early indicator’ for medtech in Q2: analyst
The company raised its revenue and earnings forecast for the year, driven by new products and global procedure growth.
By Elise Reuter • July 20, 2023 -
Courtesy of Masimo
Masimo plans cost cuts as Q2 revenue falls short of expectations
Shares of the patient-monitoring device maker dropped 22% after it said hospital orders for its equipment were delayed and demand for consumer products softened.
By Susan Kelly • July 18, 2023 -
Permission granted by Medtronic
Medtronic posts profit, sales growth in Q4, agrees to buy Korean diabetes patch maker
The company is “confident in delivering durable revenue growth in the year ahead” amid continued improvements in procedure volumes.
By Peter Green • May 25, 2023 -
Permission granted by Embecta
Embecta joins Tidepool to develop insulin pump, raises Q2 growth outlook
Embecta advanced its pump project by partnering with Tidepool, a nonprofit that has developed diabetes management software that can work across different brands of pumps and monitors.
By Nick Paul Taylor • May 15, 2023 -
Courtesy of Nuvasive
NuVasive grows sales in Q1, allaying concerns about impact of $3.1B Globus merger
The growth reflects “increased procedure volumes” and a “continued surge in demand” for NuVasive devices.
By Nick Paul Taylor • May 11, 2023 -
HadelProductions via Getty Images
ZimVie will lay off 5% of staff in bid to reduce costs, streamline business
The restructuring, along with reductions in discretionary spending, are expected to save the company $17 million to $20 million by 2024.
By Elise Reuter • May 5, 2023 -
Courtesy of Insulet Corp.
Insulet raises revenue forecast as Omnipod 5 drives US growth
Insulet is confident it can grow the market for tubeless insulin pumps in the long term, an outlook the company bases on its device’s convenience.
By Elise Reuter • May 5, 2023 -
Permission granted by iRhythm Technologies
iRhythm says it received DOJ subpoena regarding company’s ‘products and services’
The company’s shares fell more than 5% after the federal government requested documents.
By Nick Paul Taylor • May 5, 2023 -
Permission granted by Becton Dickinson
BD raises full-year forecasts again, expects Alaris infusion pump approval
The company said revenue increases in a number of its product lines were faster than market growth rates, suggesting it’s gaining share.
By Susan Kelly • May 4, 2023 -
Courtesy of Tandem Diabetes
Tandem expects to meet ‘key’ goals even as rival’s device launch may curb short-term sales growth
Tandem claims it has a better insulin pump than Medtronic’s recently approved rival MiniMed 780G device.
By Nick Paul Taylor • May 4, 2023 -
Permission granted by Zimmer Biomet
Zimmer Biomet grows revenue, profits, as orthopedic procedures return
CEO Bryan Hanson said “pretty much everything went better than expected” in the first quarter.
By Elise Reuter • May 2, 2023 -
ChooChin via Getty Images
Analyst ‘blown away’ by robot-fueled growth of Stryker’s hip and knee sales
Stryker CEO Kevin Lobo named the Mako robot as a driver of “pretty breathtaking” knee growth outside the U.S.
By Nick Paul Taylor • May 2, 2023 -
Courtesy of Hologic
Hologic, after overcoming chip shortage, starts considering larger M&A deals
The breast health unit “emphatically returned to growth” because of improvements to the supply of semiconductors.
By Nick Paul Taylor • May 2, 2023 -
Courtesy of Dexcom
Dexcom reports ‘growing momentum’ behind G7 launch in first quarter
The CGM launch helped the company add more users than in any other quarter in its history.
By Nick Paul Taylor • April 28, 2023 -
Courtesy of ResMed
ResMed device sales jump 43% as supply constraints ease
ResMed’s CEO said “I know we’ll be able to beat [Philips]” when the rival returns to the market after its recall.
By Nick Paul Taylor • April 28, 2023 -
Courtesy of Quest Diagnostics
Quest Diagnostics to pay $450M to buy liquid biopsy cancer test developer as Q1 revenue drops
The laboratory services provider said patients are returning to the healthcare system for routine care, but COVID testing has plummeted as the pandemic winds down.
By Susan Kelly • April 27, 2023
Previous
